Copyright © 2019 EnBiotix, Inc.. All Rights Reserved

A Growing Crisis in Hospital Acquired Infections:

Hospital-Acquired Infections per Year (US)
Cather-Associated Urinary Tract Infections
Add'l Treatment Cost per caUTI ($)
Annual Deaths to Resistant caUTIs

Proprietary Aminoglycoside + Potentiator I.V. Piggyback for caUTIs:

  • EBX-002 targets gram-negative persisters in hospital patients with indwelling urinary catheters
  • FDA familiarity with candidate aminoglycosides and metabolites (all FDA-approved) means abbreviated clinical development path
  • Clinical development plan should bring EBX-002 to the market within 4 years
  • EnBiotix holds patents covering the combination of aminoglycosides with a metabolite

In-vivo studies show nearly 1.5 order of magnitude reduction in bacterial load on catheters